- Home
- BLFY vs IOVA Comparison
BLFY vs IOVA Comparison
Compare BLFY & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFY
- IOVA
- Stock Information
- Founded
- BLFY 1939
- IOVA 2007
- Country
- BLFY United States
- IOVA United States
- Employees
- BLFY N/A
- IOVA N/A
- Industry
- BLFY Commercial Banks
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLFY Finance
- IOVA Health Care
- Exchange
- BLFY Nasdaq
- IOVA Nasdaq
- Market Cap
- BLFY N/A
- IOVA 1.0B
- IPO Year
- BLFY N/A
- IOVA N/A
- Fundamental
- Price
- BLFY $9.99
- IOVA $1.75
- Analyst Decision
- BLFY Hold
- IOVA Strong Buy
- Analyst Count
- BLFY 2
- IOVA 9
- Target Price
- BLFY $11.00
- IOVA $15.50
- AVG Volume (30 Days)
- BLFY 53.2K
- IOVA 13.9M
- Earning Date
- BLFY 04-30-2025
- IOVA 05-08-2025
- Dividend Yield
- BLFY N/A
- IOVA N/A
- EPS Growth
- BLFY N/A
- IOVA N/A
- EPS
- BLFY N/A
- IOVA N/A
- Revenue
- BLFY $41,228,000.00
- IOVA $212,679,000.00
- Revenue This Year
- BLFY $13.64
- IOVA $182.20
- Revenue Next Year
- BLFY $21.23
- IOVA $62.10
- P/E Ratio
- BLFY N/A
- IOVA N/A
- Revenue Growth
- BLFY N/A
- IOVA 11070.12
- 52 Week Low
- BLFY $8.30
- IOVA $2.70
- 52 Week High
- BLFY $11.48
- IOVA $13.60
- Technical
- Relative Strength Index (RSI)
- BLFY 67.13
- IOVA 23.78
- Support Level
- BLFY $9.84
- IOVA $3.02
- Resistance Level
- BLFY $10.26
- IOVA $3.31
- Average True Range (ATR)
- BLFY 0.36
- IOVA 0.24
- MACD
- BLFY 0.10
- IOVA -0.09
- Stochastic Oscillator
- BLFY 80.59
- IOVA 4.81
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.